Chemomab Therapeutics (CMMB) Current Assets (2017 - 2026)

Chemomab Therapeutics (CMMB) has reported Current Assets for 10 consecutive years, with $10.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets fell 6.19% year-over-year to $10.0 million; the trailing twelve-month figure through Jun 2026 stood at $10.0 million (down 6.19% YoY), and the FY2025 full-year result was $13.4 million, down 16.3% from the prior year.
• Current Assets declined to $10.0 million in Q2 2026 per CMMB's latest filing, from $11.5 million in the prior quarter.
• Across five years, Current Assets topped out at $59.3 million in Q1 2022 and bottomed at $10.0 million in Q2 2026.
• Historically, Current Assets has averaged $24.7 million across 5 years, with a median of $18.4 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Current Assets slipped 0.31% in 2022, then slumped 54.1% in 2023.
• Over 5 years, Current Assets stood at $41.7 million in 2022, then slumped by 49.93% to $20.9 million in 2023, then fell by 23.24% to $16.0 million in 2024, then slipped by 16.3% to $13.4 million in 2025, then declined by 25.83% to $10.0 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $10.0 million, $11.5 million, and $13.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.